scholarly journals Tumour lysis syndrome: A rare acute presentation of locally advanced testicular cancer – Case report and review of literature

2016 ◽  
Vol 3 (1) ◽  
pp. 49-52
Author(s):  
Marcus Chow ◽  
Arianto Yuwono ◽  
Ronny Tan
2013 ◽  
Vol 45 (S1) ◽  
pp. 22-24 ◽  
Author(s):  
Salvatore Lauro ◽  
Riccardo Righini ◽  
Concetta Elisa Onesti ◽  
Eugenio Pucci ◽  
Alessandra Bramini ◽  
...  

2015 ◽  
Vol 9 (1-2) ◽  
pp. 62 ◽  
Author(s):  
Kohei Kobatake ◽  
Masao Kato ◽  
Koji Mita

Tumour lysis syndrome (TLS) and choriocarcinoma syndrome (CS) are severe complications of chemotherapy for testicular cancer. They are rare, but can be life-threatening. A 37-year-old man complaining of persisting cough was referred to our hospital. A computed tomography (CT) scan revealed huge tumours that occupied the peritoneal cavity, with multiple lung, liver, and para-aortic metastases. Although there was no abnormal finding in the testes, serum testicular tumor markers showed marked elevation. A CT-guided biopsy for the peritoneal tumours revealed extragonadal germ cell tumour (GCT), including yolk sac tumour and choriocarcinoma. Chemotherapy with bleomycin, etoposide, and cisplatin (BEP) was started after admission. The morning after the beginning of BEP, the patient developed hemorrhagic shock, in addition to acute pulmonary and renal failure, because of TLS and massive hemorrhage at bilateral lung metastases. He was intubated and resuscitated. Despite appropriate therapy, his renal function did not recover and hemodialysis was started. The patient eventually died of severe respiratory distress syndrome and infection. To our knowledge, this is the first case report of TLS and CS as complications of hemorrhage at the lung metastases of advanced testicular cancer leading to death.


2011 ◽  
Vol 2 (7) ◽  
pp. 206-207 ◽  
Author(s):  
Iraklis Perysinakis ◽  
Alexander Nixon ◽  
Aggeliki Katopodi ◽  
Emmanouil Tzirakis ◽  
Despoina Georgiadou ◽  
...  

Breast Care ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. 424-426 ◽  
Author(s):  
Arpine Gevorgyan ◽  
Giacomo Bregni ◽  
Giulia Galli ◽  
Elisa Zanardi ◽  
Filippo de Braud ◽  
...  

Background: Neuroendocrine carcinoma is an uncommon histology for breast cancer. Case Report: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.


2018 ◽  
Vol 25 (4) ◽  
pp. 1006-1010 ◽  
Author(s):  
Sydney Saunders ◽  
Maria Anwar

Objective To describe a possible case of capecitabine-induced myopericarditis in a patient at the Cardio-Oncology Clinic in Calgary, AB. Design A literature search and adverse drug reaction assessment with the Naranjo tool was conducted. Results A 39-year-old male with recurrent locally advanced rectal adenocarcinoma presented two days after adjuvant treatment with capecitabine and oxaliplatin complaining of intermittent, severe interscapular pain. Based on symptoms, laboratory investigations, and imaging, the patient was diagnosed with acute myopericarditis. Management included aspirin, colchicine, and discontinuing adjuvant chemotherapy. A literature review revealed one case report of capecitabine-induced myopericarditis; however, more data were found regarding the cardiotoxicity of fluorouracil, for which capecitabine is a pro-drug. No case reports were found for oxaliplatin. Conclusion Due to the timeline of capecitabine administration, symptom onset, and improvement upon medication discontinuation, capecitabine is the probable cause of the myopericarditis. Although rare, it is important to consider the possibility of myopericarditis in patients receiving a fluoropyrimidine who present with cardiovascular symptoms.


Sign in / Sign up

Export Citation Format

Share Document